SCHEMBL490883

SCHEMBL490883

CC(C(=O)O)c1cc(O)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.60
PTGS1 P23219 2/20 0.60
CA12 O43570 5/20 0.45
CA1 P00915 5/20 0.45
CA2 P00918 5/20 0.45
CA7 P43166 5/20 0.45
CA9 Q16790 5/20 0.45
CA14 Q9ULX7 5/20 0.45
ALOX5 P09917 1/20 0.45
CYP3A4 P08684 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
TYR P14679 2/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP2C9 P11712 2/20 0.41
NR1I2 O75469 1/20 0.41
LMNA P02545 1/20 0.41
MIF P14174 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490490 0.84 TYR (0.55) PTGS2PTGS1CA12CA1CA2
SCHEMBL29429345 0.84 TYR (0.55) PTGS2PTGS1CA12CA1CA2
SCHEMBL16973495 0.81 CYP3A4 (0.42) PTGS2PTGS1CA12CA1CA2
SCHEMBL6591473 0.81 PTGS2 (0.57) PTGS2PTGS1CA1CA2CYP3A4
SCHEMBL8324702 0.81 PTGS1 (0.57) PTGS2PTGS1MEN1KMT2ACYP1A2
SCHEMBL28745580 0.78 PTGS1 (0.42) PTGS2PTGS1CYP3A4MEN1KMT2A
SCHEMBL2541518 0.78 PTGS2 (0.62) PTGS2PTGS1ALOX5MEN1KMT2A
SCHEMBL9316938 0.78 MEN1 (0.47) PTGS2PTGS1CA12CA1CA2
SCHEMBL9316933 0.78 MEN1 (0.47) PTGS2PTGS1CA12CA1CA2
SCHEMBL740967 0.78 CYP2C9 (0.48) PTGS2PTGS1CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0526302-B1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica OREAL (FR) 1995-03-01 EP claimed
US-4289495-A HAIR DYES, STORAGE STABILITY L'OREAL (FR) 1981-09-15 US claimed
US-8505730-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2013-08-13 US disclosed
US-20120312717-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2012-12-13 US disclosed
US-8273791-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2012-09-25 US disclosed
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
EP-2087880-A2 Compositions, kits and regimens for the treatment of skin, especially décolletage Jr Chem, LLC (US) 2009-08-12 EP disclosed
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2009-07-09 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20010036446-A1 Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives L'OREAL (FR) 2001-11-01 US disclosed
US-5667792-A CARBOXY DERIVATIVES OF HYDROQUINONE AS BLEACHES FOR SKIN L'OREAL (FR) 1997-09-16 US disclosed
US-5637756-A TREATMENT OF SKIN DISORDERS, BLEACHING OF PIGMENTED SPOTS, COSMETICS L'OREAL (FR) 1997-06-10 US disclosed
US-5587173-A Utilization of derivatives of 2,5 dihydroxyphenyl-carboxylic acid amides and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action L'OREAL (FR) 1996-12-24 US disclosed
US-5585105-A Utilization of derivatives of 2,5-dihydroxyphenylcarboxylic acids, their homologs, and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action L'OREAL (FR) 1996-12-17 US disclosed
EP-0526302-B1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica OREAL (FR) 1995-03-01 EP disclosed
EP-0526302-A1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica L'OREAL (FR) 1993-02-03 EP disclosed
US-4265807-A TO INCREASE ITS OXIDATION RESISTANCE HERCULES INCORPORATED (US) 1981-05-05 US disclosed
US-3979506-A Radioactive compounds for labeling proteins PIERCE CHEMICAL COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 PTGS2 1873/4885PTGS1 1937/4885CA12 2109/4885
US-20090176876-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE RARG, RARA, RXRG PTGS2 1236/4885PTGS1 1464/4885CA12 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.